These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18677210)

  • 1. Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol.
    Becker S; Laffont S; Vitry F; Rolland Y; Lecloirec J; Boucher E; Raoul JL; Herry JY; Bourguet P; Garin E
    Nucl Med Commun; 2008 Sep; 29(9):815-25. PubMed ID: 18677210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary?
    Bacher K; Brans B; Monsieurs M; De Winter F; Dierckx RA; Thierens H
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1311-6. PubMed ID: 12271412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
    J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient dosimetry for 131I-lipiodol therapy.
    Monsieurs MA; Bacher K; Brans B; Vral A; De Ridder L; Dierckx RA; Thierens HM
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):554-61. PubMed ID: 12690415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.
    Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol].
    Raoul JL; Duvauferrier R; Bourguet P; Bretagne JF; Coornaert S; Darnault P; Deugnier Y; Herry JY; Gastard J
    J Radiol; 1986 Nov; 67(11):797-801. PubMed ID: 3027321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of hepatocellular carcinoma with 131I-lipiodol: patient dosimetry.
    Risse JH; Pauleit D; Palmedo H; Bender H; Bucerius J; Ezziddin S; Klein V; Grünwald F; Biersack HJ; Reichmann K
    Nuklearmedizin; 2007; 46(5):192-7. PubMed ID: 17938753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol.
    Kumar A; Bal C; Srivastava DN; Thulkar SP; Sharma S; Acharya SK; Duttagupta S
    Eur J Gastroenterol Hepatol; 2006 Feb; 18(2):219-23. PubMed ID: 16394805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of lipiodol agent on proton beam range in radiotherapy planning using computed tomography for hepatocellular carcinoma.
    Shin D; Kim TH; Park SY; Kwak J; Moon SH; Yoon M; Lee SB; Park S; Shin KH; Kim DY; Cho KH; Park JW; Kim CM
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):687-94. PubMed ID: 18448269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
    Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F
    J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres.
    Chiesa C; Mira M; Maccauro M; Romito R; Spreafico C; Sposito C; Bhoori S; Morosi C; Pellizzari S; Negri A; Civelli E; Lanocita R; Camerini T; Bampo C; Carrara M; Seregni E; Marchianò A; Mazzaferro V; Bombardieri E
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):503-8. PubMed ID: 23358402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma.
    Shinto AS; Karuppusamy KK; Kurup RER; Pandiyan A; Jayaraj AV
    Nucl Med Commun; 2021 Jan; 42(1):43-50. PubMed ID: 32956248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective radionuclide localisation in primary liver tumours (pilot study).
    Novell JR; Green AJ; Hilson AJ; Dusheiko G; Dick R; Hobbs KE
    HPB Surg; 1994; 7(3):185-99; discussion 200. PubMed ID: 8155585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres.
    Dieudonné A; Garin E; Laffont S; Rolland Y; Lebtahi R; Leguludec D; Gardin I
    J Nucl Med; 2011 Dec; 52(12):1930-7. PubMed ID: 22068894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
    Bernal P; Raoul JL; Stare J; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Vidmar G; Buscombe J; Chau TT; Saw MM; Chen S; Ogbac R; Dondi M; Padhy AK
    Semin Nucl Med; 2008 Mar; 38(2):S40-5. PubMed ID: 18243842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with
    Delaunay K; Edeline J; Rolland Y; Lepareur N; Laffont S; Palard X; Bouvry C; Le Sourd S; Pracht M; Ardisson V; Noiret N; Bellissant É; Garin E
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1506-1517. PubMed ID: 30715571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-lipiodol therapy for hepatocellular carcinoma.
    Garin E; Laffont S; Rolland Y; Olivie D; Lecloirec J; Herry JY; Boucher E; Raoul JL; Bourguet P
    Nucl Med Commun; 2003 Jun; 24(6):671-8. PubMed ID: 12766603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma.
    Leung WT; Lau WY; Ho S; Chan M; Leung N; Lin J; Ho KC; Metreweli C; Johnson PJ; Li AK
    J Nucl Med; 1994 Aug; 35(8):1313-8. PubMed ID: 7519259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.
    Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP
    Radiology; 2007 May; 243(2):509-19. PubMed ID: 17456873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma.
    Brans B; Van Laere K; Gemmel F; Defreyne L; Vanlangenhove P; Troisi R; Van Vlierberghe H; Colle I; De Hemptinne B; Dierckx RA
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):928-32. PubMed ID: 12111134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.